

World Journal of *Cardiology*

World J Cardiol 2024 April 26; 16(4): 168-216



EDITORIAL

- 168 Pacemaker post transcatheter aortic valve replacement: A multifactorial risk?
Noble S, Bendjelid K
- 173 Challenging situation of coronary artery anomaly associated with ischemia and/or risk of sudden death
Ito S
- 177 Transcatheter aortic valve replacement in low-risk young population: A double edge sword?
Bhogal S, Batta A
- 181 Hypoxia-inducible factor-1 α in myocardial infarction
Škrlec I, Kolomeichuk SN
- 186 Left bundle branch pacing set to outshine biventricular pacing for cardiac resynchronization therapy?
Batta A, Hatwal J

MINIREVIEWS

- 191 Aspirin interruption before neurosurgical interventions: A controversial problem
Kulikov A, Konovalov A, Pugnaroni PP, Bilotta F

SCIENTOMETRICS

- 199 The cardiovascular system at high altitude: A bibliometric and visualization analysis
Zhao ML, Lu ZJ, Yang L, Ding S, Gao F, Liu YZ, Yang XL, Li X, He SY

CORRECTION

- 215 Correction: Establishment of a prediction model for prehospital return of spontaneous circulation in out-of-hospital patients with cardiac arrest
Wang JJ, Zhou Q, Huang ZH, Han Y, Qin CZ, Chen ZQ, Xiao XY, Deng Z

ABOUT COVER

Peer Reviewer of *World Journal of Cardiology*, Ramachandra Barik, DNB, MD, Full Professor, Department of Cardiology, All India Institute of Medical Sciences, Bhubaneswar 751019, Odisha, India.
cardioramachandra@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Cardiology (WJC, World J Cardiol)* is to provide scholars and readers from various fields of cardiology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJC mainly publishes articles reporting research results and findings obtained in the field of cardiology and covering a wide range of topics including acute coronary syndromes, aneurysm, angina, arrhythmias, atherosclerosis, atrial fibrillation, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, hypertension, imaging, infection, myocardial infarction, pathology, peripheral vessels, public health, Raynaud's syndrome, stroke, thrombosis, and valvular disease.

INDEXING/ABSTRACTING

The WJC is now abstracted and indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJC as 1.9; IF without journal self cites: 1.8; 5-year IF: 2.3; Journal Citation Indicator: 0.33. The WJC's CiteScore for 2022 is 1.9 and Scopus CiteScore rank 2022: Cardiology and cardiovascular medicine is 226/354.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Si Zhao; Production Department Director: Xiang Li; Cover Editor: Yun-Xiaojiao Wu.

NAME OF JOURNAL

World Journal of Cardiology

ISSN

ISSN 1949-8462 (online)

LAUNCH DATE

December 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Ramdas G Pai, Dimitrios Tousoulis, Marco Matteo Ciccone, Pal Pacher

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/1949-8462/editorialboard.htm>

PUBLICATION DATE

April 26, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Hypoxia-inducible factor-1 α in myocardial infarction

Ivana Škrlec, Sergey N Kolomeichuk

Specialty type: Biochemistry and molecular biology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Adam CA, Romania;
Kawaguchi N, Japan

Received: December 13, 2023

Peer-review started: December 13, 2023

First decision: January 15, 2024

Revised: January 26, 2024

Accepted: March 4, 2024

Article in press: March 4, 2024

Published online: April 26, 2024



Ivana Škrlec, Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek 31000, Croatia

Sergey N Kolomeichuk, Institute of Biology, Karelia Research Center of Russian Academy of Sciences, Petrozavodsk 185910, Russia

Sergey N Kolomeichuk, Laboratory for Genomics, Proteomics, and Metabolomics, Research Institute of Biomedicine and Biomedical Technologies, Tyumen State Medical University, Tyumen 625023, Russia

Corresponding author: Ivana Škrlec, MSc, PhD, Assistant Professor, Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Crkvena 21, Osijek 31000, Croatia. iskrlec@fdmz.hr

Abstract

Hypoxia-inducible factor 1 (HIF1) has a crucial function in the regulation of oxygen levels in mammalian cells, especially under hypoxic conditions. Its importance in cardiovascular diseases, particularly in cardiac ischemia, is because of its ability to alleviate cardiac dysfunction. The oxygen-responsive subunit, HIF1 α , plays a crucial role in this process, as it has been shown to have cardioprotective effects in myocardial infarction through regulating the expression of genes affecting cellular survival, angiogenesis, and metabolism. Furthermore, HIF1 α expression induced reperfusion in the ischemic skeletal muscle, and hypoxic skin wounds in diabetic animal models showed reduced HIF1 α expression. Increased expression of HIF1 α has been shown to reduce apoptosis and oxidative stress in cardiomyocytes during acute myocardial infarction. Genetic variations in HIF1 α have also been found to correlate with altered responses to ischemic cardiovascular disease. In addition, a link has been established between the circadian rhythm and hypoxic molecular signaling pathways, with HIF1 α functioning as an oxygen sensor and circadian genes such as period circadian regulator 2 responding to changes in light. This editorial analyzes the relationship between HIF1 α and the circadian rhythm and highlights its significance in myocardial adaptation to hypoxia. Understanding the changes in molecular signaling pathways associated with diseases, specifically cardiovascular diseases, provides the opportunity for innovative therapeutic interventions, especially in low-oxygen environments such as myocardial infarction.

Key Words: Cardiovascular pathologies; Circadian genes; Hypoxia-inducible factor 1; Hypoxia; Gene-gene interaction

Core Tip: Hypoxia-inducible factor 1 (HIF1), a versatile transcription factor, is crucial for the maintenance of oxygen homeostasis. Genetic variations in *HIF1 α* may influence tissue response to hypoxia and affect clinical manifestations of coronary atherosclerosis. Research has confirmed that sufficient *HIF1 α* expression leads to reperfusion in the ischemic skeletal muscle, whereas decreased expression is associated with hypoxic skin wounds in diabetic animal models. In addition, the HIF1 α response can be influenced by circadian proteins. Interpretation of circadian and hypoxia signaling pathways may enable therapeutic interventions in diseases associated with oxygen deprivation, including myocardial infarction.

Citation: Škrlec I, Kolomeichuk SN. Hypoxia-inducible factor-1 α in myocardial infarction. *World J Cardiol* 2024; 16(4): 181-185

URL: <https://www.wjgnet.com/1949-8462/full/v16/i4/181.htm>

DOI: <https://dx.doi.org/10.4330/wjc.v16.i4.181>

INTRODUCTION

Hypoxia-inducible factor 1 (HIF1) is a central regulator of oxygen homeostasis in mammalian cells and is activated under hypoxic conditions[1]. Hypoxia is a hallmark of many physiological and pathological conditions, and a stable HIF1 α protein is essential for the adaptation and survival of cells in an oxygen-deprived environment – hypoxia[2]. In addition, HIF1 contributes to several hypoxia-related diseases, including cardiovascular diseases[1]. Oxidative metabolism is essential for the maintenance of cardiac contractility as it produces a large amount of ATP. Therefore, the heart is extremely sensitive to hypoxia, and myocardial ischemia is the leading cause of death in developed countries[3]. Oxygen-sensitive signaling pathways, such as HIF1 α , are important for adapting to changes in oxygen availability during myocardial ischemia. HIF1 α protein levels are regulated post-transcriptionally and are inversely proportional to oxygen levels[4]. HIF1 α is involved in vascular responses to hypoxia, such as ischemia-induced angiogenesis and lipid metabolism, glucose catabolism, and redox homeostasis. The genetic variability of *HIF1 α* is associated with cardiovascular diseases, such as coronary heart disease, ischemic heart disease, preeclampsia, and acute myocardial infarction[2].

HIF1 α SUBUNIT

HIF1 is a transcription factor that consists of two subunits, α and β . The HIF1 α subunit is oxygen-sensitive, whereas HIF1 β is constitutively expressed[3]. The gene sequence encoding the HIF1 α subunit is located on the long arm of chromosome 14 (14q23.2) and plays an important role in regulating cellular processes to maintain oxygen homeostasis[5]. In mammals, there are three different variants of the HIF α protein, with HIF1 α being ubiquitously expressed in all cells, whereas the expression of HIF2 α and HIF3 α varies according to cell type and tissue[2]. Under conditions of oxygen deprivation - hypoxia - the expression of most genes is repressed at the transcriptional level. In contrast, the expression of a specific group of genes, the so-called hypoxia-inducible genes, is increased under hypoxic conditions[6]. These genes include erythropoietin, vascular endothelial growth factor, and genes involved in cell metabolism and inflammation[7]. Under normoxia, HIF1 α is subject to oxygen-dependent hydroxylation. It is degraded by prolyl hydroxylase, an E3 ubiquitin ligase, and by the von Hippel-Lindau degradation pathway in the ubiquitin-proteasome system[1,4]. Under hypoxic conditions, HIF1 α is prevented from degradation, accumulates, and migrates to the nucleus[6]. In the nucleus, the α -subunit of HIF1 forms a heterodimer with the β -subunit, resulting in a transcription factor that promotes cell survival, angiogenesis, and glycolysis[8]. HIF1 α binds to hypoxia-responsive elements in the nucleus and activates the transcription of hypoxia-inducible genes[6] (Figure 1). It also stimulates gene transcription by binding to a specific DNA sequence 5'-RCGTG-3' (where R can be an A or G) within the hypoxia-responsive elements[9]. HIF1 α stimulates the transcription of genes responsible for the production of enzymes, transporters, and mitochondrial proteins. These genes contribute to the reduction in oxygen consumption and control the transition of cells from oxidative to glycolytic metabolism[9]. When oxygen levels are reduced, the degradation of HIF1 α is inhibited, leading to a strong accumulation of HIF1 α [4].

In addition, changes in the nucleotide sequence or expression of the HIF1 α subunit are associated with the development of various diseases[2]. *HIF1 α* polymorphisms, such as rs11549465 (Pro582Ser) and rs2057482, may impair the response to tissue hypoxia and influence the clinical manifestations of coronary atherosclerosis by affecting HIF1 α subunit degradation and *HIF1 α* mRNA stability[8]. The rs11549467 polymorphism is also important for HIF1 α subunit stability[5]. The *HIF1 α* rs2057482 polymorphism is a risk factor for the development of premature coronary heart disease [5]. These variations may influence the tissue response to hypoxia and affect the clinical manifestations of coronary atherosclerosis[8].




Figure 1 Molecular effects of hypoxia-inducible factor 1 α under normal oxygen conditions and under oxygen deprivation. Under normal oxygen conditions, hypoxia-inducible factor 1 α (HIF1 α) is degraded by the ubiquitin-proteasome system via an oxygen-dependent pathway involving prolyl hydroxylases, the von Hippel-Lindau protein, and an E3 ubiquitin ligase. In the case of an oxygen shortage – hypoxia, HIF1 α in the cell nucleus dimerizes with HIF1 β , and binds itself to hypoxia response elements, which are associated with hypoxia-inducible genes. Furthermore, the HIF1 α -basic helix-loop-helix ARNT like 1 (BMAL1) heterodimer binds to the specific E-box region of circadian genes, thereby enhancing the expression of period circadian regulator 2 and cryptochrome circadian regulator 1. In addition, the BMAL1-circadian locomotor output cycles kaput heterodimer enhances *HIF1 α* expression under hypoxic conditions. HIF1 α : Hypoxia-inducible factor 1 α ; PHD: Prolyl hydroxylases; vHL: von Hippel-Lindau protein; HRE: Hypoxia response elements; BMAL1: Basic helix-loop-helix ARNT like 1; PER2: Period circadian regulator 2; CRY1: Cryptochrome circadian regulator 1; CLOCK: Circadian locomotor output cycles kaput.

HIF1 α IN MYOCARDIAL INFARCTION

Cardiovascular diseases are prone to ischemic injury[2]. In these diseases, such as atherosclerosis and myocardial infarction, the oxygen supply to cells is reduced owing to impaired blood flow, eventually leading to tissue hypoxia[6], and cardiac hypoxia or ischemia[1]. Mammalian cells respond quickly and adapt to hypoxic conditions[2]. HIF1 α plays a significant role in this process and confers cardioprotective effects to deoxygenated myocardium[2]. In humans, HIF1 α insufficiency may correlate in part with congenital heart abnormalities[9]. HIF1 α directly regulates over 1000 genes in the human genome during hypoxia, most of which are expressed in a specific cell type[9]. It is important to emphasize that this regulation is not an indirect, but a direct effect of HIF1 α .

HIF1 α acts as a cellular oxygen sensor in cardiomyocytes[10]. Its overexpression in the heart during acute myocardial infarction leads to the upregulation of proangiogenic HIF1 α target genes, resulting in reduced cardiac dysfunction and decreased cardiomyocyte apoptosis[7]. In addition, excessive levels of HIF1 α promote the expression of heme oxygenase-1 (HO-1), which reduces the accumulation of reactive oxygen species[10]. Moreover, increased *HIF1 α* expression suppresses the pro-apoptotic gene BCL2 interacting protein-3 (BNIP3) via the nuclear factor kappa B (NF- κ B) protein. *HIF1 α* expression increases during myocardial infarction and serves as a regulator of the cellular hypoxia response[10]. The Pro582Ser (rs11549465) polymorphism in *HIF1 α* affects the response to ischemic cardiovascular diseases. Furthermore, inhibition of *HIF1 α* or *HIF1 β* expression in myocardial endothelial cells leads to a lack of acute cardioprotection after ischemic preconditioning[9]. Inhibition of *HIF1 α* in the myocardium could either promote or impair cardiomyocyte apoptosis. Increased expression of *HIF1 α* in myocardial infarction significantly reduces the size of the infarct and restores the typical histologic structure of the myocardium. In addition, overexpression of *HIF1 α* reduces the oxidative stress load during myocardial infarction[10]. Increased *HIF1 α* expression promotes NF- κ B binding to the *BNIP3* promoter, which reduces *BNIP3* expression and BNIP3-mediated apoptotic activity in hypoxic cardiomyocytes[10]. The signaling pathways mediated by HIF1 α and NF- κ B show synergistic interaction to reduce cardiomyocyte apoptosis. Increased cardiac-specific *HIF1 α* expression during myocardial infarction leads to differential regulation of HO-1 and BNIP3 expression by HIF1 α and NF- κ B[10], demonstrating the crucial role of these signaling pathways in cardioprotection. In addition, HIF1 α influences the balance between glycolytic and oxidative metabolism, with elevated levels of HIF1 α leading to the expression of genes responsible for glucose transporters and glycolytic enzymes[9]. As a result, expression of *HIF1 α* has been shown to be sufficient to trigger reperfusion in the ischemic skeletal muscle. However, *HIF1 α* expression was reduced in the hypoxic skin wounds of old diabetic mice[2]. HIF1 α may have a protective, proangiogenic, and pathogenic effect during infarction as it regulates metabolic reprogramming leading to energy

depletion[9].

Cardiac hypoxia is usually caused by myocardial ischemia, which occurs when the metabolic needs of the heart muscle are not met owing to insufficient oxygen supply[2]. Arterial stenosis-induced hypoxia promotes the expression of HIF1 α , which in turn stimulates the production of angiogenic growth factors, leading to vascular remodeling and increased blood flow. HIF1 α is essential for ischemic preconditioning as it reduces reactive oxygen species production, protecting the heart from injury[9]. Chronic disease and aging impede this response. HIF1 α plays a multifaceted role in the pathophysiology of myocardial infarction. It may be protective by promoting angiogenesis or pathologic through maladaptive metabolic reprogramming[9].

Different genetic variations of HIF1 α can potentially affect the risk of myocardial infarction by influencing numerous mechanisms. Cardiac ischemia induces strong HIF1 α expression, which could stimulate the formation of new blood vessels near the coronary arteries. Variations in HIF1 α may alter the risk of acute myocardial infarction by inhibiting the development of new blood vessels near the atherosclerotic plaques in the coronary arteries[8]. Certain polymorphisms of HIF1 α have been associated with cardiovascular diseases, including rs11549465, rs10873142, rs2057482, rs11549467, rs41508050, rs2783778, and rs7148720[2]. Several studies have investigated the association between different polymorphisms of HIF1 α and cardiovascular diseases. However, conflicting and controversial results have been reported, indicating both positive and negative associations between HIF1 α variations and cardiovascular diseases[5,8].

HIF1 α AND THE CIRCADIAN RHYTHM IN MYOCARDIAL INFARCTION

Research has indicated a link between circadian and hypoxic molecular pathways. HIF1 α acts as an oxygen sensor, whereas period circadian regulator 2 (PER2) acts as a light sensor[7]. In response to HIF1 α , several circadian rhythm genes respond to changes in oxygen levels[4]. HIF1 α is able to induce the expression of PER2 and cryptochrome circadian regulator 1 (CRY1)[1]. Stabilization of HIF1 α by PER2 is necessary for myocardial adaptation to hypoxia[11]. HIF1 α regulates the hypoxic response to myocardial infarction *via* the circadian rhythm and influences the expression of target genes[1]. The adaptation of cardiomyocytes to hypoxia, known as ischemic demand, makes them more resistant to infarction by expressing high levels of PER2 and HIF1 α [11]. HIF1 α , HIF1 β , basic helix-loop-helix ARNT like 1 (BMAL1), and circadian locomotor output cycles kaput (CLOCK) are transcription factors that respond to physiological and environmental signals. In addition, HIF1 α can regulate circadian rhythms, whereas circadian proteins have the ability to influence the HIF1 α response[12]. Additionally, similar to BMAL1, HIF1 α contains a basic helix-loop-helix - period-ARNT-single minded (bHLH-PAS) domain. Through this domain, it dimerizes with BMAL1 and stimulates the expression of target genes. Thus, HIF1 α serves as a molecular link between oxygen levels and the circadian rhythm[13].

The HIF1 α -BMAL1 heterodimer binds to the same E-box regions of target genes as the CLOCK-BMAL1 heterodimer and influences the expression of downstream genes such as PER2, CRY1, and HIF1 α target genes[1] (Figure 1). HIF1 α is associated with vascular inflammation and the progression of atherosclerosis, whereas CLOCK and BMAL1 can also promote HIF1 α expression[1]. Furthermore, myocardial ischemia triggers pathways to improve oxygen delivery and, during hypoxia, PER2 interacts with HIF1 α [13]. This occurs because PER2 stabilizes HIF1 α *via* adenosine receptor A2B (ADORA2B), which is crucial for myocardial adaptation to hypoxia[14]. Additionally, daily rhythms are present in blood and tissue oxygenation, oxygen usage, and carbon dioxide release. Exposure to hypoxia leads to tissue- and time-specific changes in the expression of circadian clock genes. Myocardial tissue damage is associated with the time of day of infarction, suggesting a link between HIF1 α and circadian regulation of infarction[15]. Severe hypoxia-induced outcomes, namely myocardial infarction, are associated with changes in circadian rhythm. The circadian rhythm plays a crucial role in fine-tuning hypoxic responses during pathological circumstances[15].

Mice lacking *Per2* are unable to maintain the stability of the HIF1 α subunit in the myocardium during hypoxia, leading to increased cardiomyocyte death during ischemia[1]. Furthermore, myocardial damage after myocardial infarction appears to be worse in mice lacking *Per1* and *Per2* than in wild-type mice[15]. Within the physiological range, the oxygen cycle appropriately synchronizes cellular circadian clocks through a HIF1 α -dependent mechanism. A slight reduction in oxygen levels for a short period of time facilitates adaptation to the time changes after jet lag in wild-type mice, but not in HIF1 α -null mice[4].

Hypoxia and changing oxygen levels affect the circadian rhythm through different mechanisms involving HIF1 α [1]. The circadian rhythm protects the heart muscle from hypoxia-induced cell death[1].

CONCLUSION

The relationship between hypoxia and circadian molecular signaling pathways needs further clarification in many physiological and pathophysiological processes, as these pathways are evolutionarily conserved and allow cells to adapt to unfavorable environmental conditions. The timing of the experiment significantly influences the circadian rhythm and, subsequently, HIF1 α levels, which are associated with the severity of cardiovascular diseases. Studying the use of molecular signaling pathways in tissues and how they are influenced by specific diseases, particularly in the context of cardiovascular disease, presents new therapeutic possibilities for the treatment of diseases with low oxygen availability, such as myocardial infarction.

FOOTNOTES

Author contributions: Škrlec I did the majority of the writing and prepared the figure; Kolomeychuk SN did some writing and text editing.

Supported by Croatian Ministry of Science and Education, Josip Juraj Strossmayer University of Osijek, Faculty of Dental Medicine and Health, Osijek, Croatia, No. IP7-FDMZ-2023; West-Siberian Science and Education Center, Government of Tyumen District, Decree of 20.11.2020, No. 928-rp; and Ministry of Science and Higher Education, No. FMEN 2022-0009.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Croatia

ORCID number: Ivana Škrlec 0000-0003-1842-930X; Sergey N Kolomeichuk 0000-0003-3104-3639.

S-Editor: Gong ZM

L-Editor: A

P-Editor: Guo X

REFERENCES

- O'Connell EJ, Martinez CA, Liang YG, Cistulli PA, Cook KM. Out of breath, out of time: interactions between HIF and circadian rhythms. *Am J Physiol Cell Physiol* 2020; **319**: C533-C540 [PMID: 32726159 DOI: 10.1152/ajpcell.00305.2020]
- Gladek I, Ferdin J, Horvat S, Calin GA, Kunej T. HIF1A gene polymorphisms and human diseases: Graphical review of 97 association studies. *Genes Chromosomes Cancer* 2017; **56**: 439-452 [PMID: 28165644 DOI: 10.1002/gcc.22449]
- Knutson AK, Williams AL, Boisvert WA, Shohet RV. HIF in the heart: development, metabolism, ischemia, and atherosclerosis. *J Clin Invest* 2021; **131** [PMID: 34623330 DOI: 10.1172/JCI1137557]
- Adamovich Y, Ladeuix B, Golik M, Koeners MP, Asher G. Rhythmic Oxygen Levels Reset Circadian Clocks through HIF1α. *Cell Metab* 2017; **25**: 93-101 [PMID: 27773695 DOI: 10.1016/j.cmet.2016.09.014]
- López-Reyes A, Rodríguez-Pérez JM, Fernández-Torres J, Martínez-Rodríguez N, Pérez-Hernández N, Fuentes-Gómez AJ, Aguilar-González CA, Alvarez-León E, Posadas-Romero C, Villarreal-Molina T, Pineda C, Vargas-Alarcón G. The HIF1A rs2057482 polymorphism is associated with risk of developing premature coronary artery disease and with some metabolic and cardiovascular risk factors. The Genetics of Atherosclerotic Disease (GEA) Mexican Study. *Exp Mol Pathol* 2014; **96**: 405-410 [PMID: 24769354 DOI: 10.1016/j.yexmp.2014.04.010]
- Abe H, Semba H, Takeda N. The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases. *J Atheroscler Thromb* 2017; **24**: 884-894 [PMID: 28757538 DOI: 10.5551/jat.RV17009]
- Bartman CM, Eckle T. Circadian-Hypoxia Link and its Potential for Treatment of Cardiovascular Disease. *Curr Pharm Des* 2019; **25**: 1075-1090 [PMID: 31096895 DOI: 10.2174/1381612825666190516081612]
- Hlatky MA, Quertermous T, Boothroyd DB, Priest JR, Glassford AJ, Myers RM, Fortmann SP, Iribarren C, Tabor HK, Assimes TL, Tibshirani RJ, Go AS. Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. *Am Heart J* 2007; **154**: 1035-1042 [PMID: 18035072 DOI: 10.1016/j.ahj.2007.07.042]
- Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. *Annu Rev Physiol* 2014; **76**: 39-56 [PMID: 23988176 DOI: 10.1146/annurev-physiol-021113-170322]
- Datta Chaudhuri R, Banik A, Mandal B, Sarkar S. Cardiac-specific overexpression of HIF-1α during acute myocardial infarction ameliorates cardiomyocyte apoptosis via differential regulation of hypoxia-inducible pro-apoptotic and anti-oxidative genes. *Biochem Biophys Res Commun* 2021; **537**: 100-108 [PMID: 33388412 DOI: 10.1016/j.bbrc.2020.12.084]
- Škrlec I, Marić S, Včev A. Myocardial infarction and circadian rhythm [Internet]. In: Angelos Tshipis. Visions of Cardiomyocyte - Fundamental Concepts of Heart Life and Disease. London, UK: IntechOpen; 2020: 21-35. Available from: <https://www.intechopen.com/online-first/myocardial-infarction-and-circadian-rhythm>
- Egg M, Köblitz L, Hirayama J, Schwerte T, Folterbauer C, Kurz A, Fiechtner B, Möst M, Salvenmoser W, Sassone-Corsi P, Pelster B. Linking oxygen to time: the bidirectional interaction between the hypoxic signaling pathway and the circadian clock. *Chronobiol Int* 2013; **30**: 510-529 [PMID: 23421720 DOI: 10.3109/07420528.2012.754447]
- Škrlec I. Circadian system microRNAs - Role in the development of cardiovascular diseases. *Adv Protein Chem Struct Biol* 2023; **137**: 225-267 [PMID: 37709378 DOI: 10.1016/bs.apcsb.2023.02.004]
- Eckle T, Hartmann K, Bonney S, Reithel S, Mittelbronn M, Walker LA, Lowes BD, Han J, Borchers CH, Buttrick PM, Kominsky DJ, Colgan SP, Eltzschig HK. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. *Nat Med* 2012; **18**: 774-782 [PMID: 22504483 DOI: 10.1038/nm.2728]
- Wu Y, Tang D, Liu N, Xiong W, Huang H, Li Y, Ma Z, Zhao H, Chen P, Qi X, Zhang EE. Reciprocal Regulation between the Circadian Clock and Hypoxia Signaling at the Genome Level in Mammals. *Cell Metab* 2017; **25**: 73-85 [PMID: 27773697 DOI: 10.1016/j.cmet.2016.09.009]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

